Literature DB >> 12884169

Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?

Thomas P Giordano1, John A Wright, Mirza Q Hasan, A Clinton White, Edward A Graviss, Fehmida Visnegarwala.   

Abstract

To determine whether CD4 cell count response to virus suppression during highly active antiretroviral therapy differs according to sex or race/ethnicity, we analyzed data in our observational cohort study for patients receiving their first antiretroviral regimen who experienced virus suppression by 6 months of therapy. In both univariate and multivariate analyses, women had greater CD4 cell count increases, compared with men, as did patients receiving a regimen that did not include a protease inhibitor. Race/ethnicity was not a factor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884169     DOI: 10.1086/376638

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

1.  Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.

Authors:  Julia L Marcus; Wendy A Leyden; Chun R Chao; Lanfang Xu; Charles P Quesenberry; Phyllis C Tien; Daniel B Klein; William J Towner; Michael A Horberg; Michael J Silverberg
Journal:  AIDS Patient Care STDS       Date:  2015-05-18       Impact factor: 5.078

2.  Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care.

Authors:  Michael J Silverberg; Wendy Leyden; Charles P Quesenberry; Michael A Horberg
Journal:  J Gen Intern Med       Date:  2009-07-16       Impact factor: 5.128

3.  Role of Education in HIV Clinical Outcomes in a Tuberculosis Endemic Setting.

Authors:  Gabriel M Cohen; Lise Werner; Santhanalakshmi Gengiah; Kogieleum Naidoo
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-05-24

4.  Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.

Authors:  Mhairi Maskew; Alana T Brennan; Daniel Westreich; Lynne McNamara; A Patrick MacPhail; Matthew P Fox
Journal:  J Womens Health (Larchmt)       Date:  2013-01-25       Impact factor: 2.681

5.  Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Authors:  Kathleen E Squires; Linda-Gail Bekker; Joseph J Eron; Benjamin Cheng; Juergen K Rockstroh; Farid Marquez; Princy Kumar; Melanie Thompson; Rafael E Campo; Karam Mounzer; Kim M Strohmaier; Chengxing Lu; Anthony Rodgers; Beth E Jackson; Larissa A Wenning; Michael Robertson; Bach-Yen T Nguyen; Peter Sklar
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-26       Impact factor: 2.205

6.  Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women.

Authors:  Jerome Kerzerho; Elizabeth J McIlvaine; Patricia Anthony; Wendy J Mack; Chia-Hao Wang; Toni Frederick; Eva Operskalski; Zhi Chen; Lena Al-Harthi; Alan Landay; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Omid Akbari; Elizabeth T Golub; Gerald B Sharp; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

7.  Beyond the Brain: The Role of Brain-Derived Neurotrophic Factor in Viroimmune Responses to Antiretroviral Therapy among People Living with HIV with and without Alcohol Use.

Authors:  María José Míguez-Burbano; Luis Espinoza; Diego Bueno; Mayra Vargas; Allison B Trainor; Clery Quiros; John E Lewis; Deshratn Asthana
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-05-16

8.  The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda.

Authors:  Brian K Kigozi; Samwel Sumba; Peter Mudyope; Betty Namuddu; Joan Kalyango; Charles Karamagi; Mathew Odere; Elly Katabira; Peter Mugyenyi; Francis Ssali
Journal:  AIDS Res Ther       Date:  2009-07-24       Impact factor: 2.250

9.  Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.

Authors:  Sarah J Willis; Stephen R Cole; Daniel Westreich; Andrew Edmonds; Christopher B Hurt; Svenja Albrecht; Kathryn Anastos; Michael Augenbraun; Margaret Fischl; Audrey L French; Aley G Kalapila; Roksana Karim; Marion G Peters; Michael Plankey; Eric C Seaberg; Phyllis C Tien; Adaora A Adimora
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

10.  Treatment initiation, program attrition and patient treatment outcomes associated with scale-up and decentralization of HIV care in rural Malawi.

Authors:  Megan McGuire; Loretxu Pinoges; Rupa Kanapathipillai; Tamika Munyenyembe; Martha Huckabee; Simon Makombe; Elisabeth Szumilin; Annette Heinzelmann; Mar Pujades-Rodríguez
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.